Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Russell

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|November 3, 2012
Improving outcomes for elderly patients with AMLNigel H Russell
Experimental Hematology|May 29, 2002
Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cellsPhennapha Klangsinsirikul, Nigel H Russell
Haematologica|January 15, 2026
All patients with acute myeloid leukemia and <i>FLT3</i>-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the CONNigel H Russell, Katie D Lewis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2025
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AMLNigel H Russell, Abin Thomas, Sylvie D Freeman
BMC Cancer|June 18, 2011
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPAMartin Grundy, Claire Seedhouse, Nigel H Russell, et al.
Blood|June 9, 2016
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Defining conditioning regimens for BMT--recognition of "regimens of intermediate intensity"Nigel H Russell, Jennifer I Byrne, Stephen P Robinson
Leukemia|January 18, 2019
Targeting FLT3 mutations in AML: review of current knowledge and evidenceNaval Daver, Richard F Schlenk, Nigel H Russell, et al.
British Journal of Haematology|November 20, 2021
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trialsRichard Dillon, Robert K Hills, Alan K Burnett, et al.
Blood|November 2, 2002
CMV infection following nonmyeloablative allogeneic stem cell transplantation using CampathRowena D Bainton, Jennifer L Byrne, Barbara J Davy, et al.
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|November 3, 2012
Improving outcomes for elderly patients with AMLNigel H Russell
Experimental Hematology|May 29, 2002
Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cellsPhennapha Klangsinsirikul, Nigel H Russell
Haematologica|January 15, 2026
All patients with acute myeloid leukemia and <i>FLT3</i>-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the CONNigel H Russell, Katie D Lewis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2025
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AMLNigel H Russell, Abin Thomas, Sylvie D Freeman
BMC Cancer|June 18, 2011
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPAMartin Grundy, Claire Seedhouse, Nigel H Russell, et al.
Blood|June 9, 2016
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Defining conditioning regimens for BMT--recognition of "regimens of intermediate intensity"Nigel H Russell, Jennifer I Byrne, Stephen P Robinson
Leukemia|January 18, 2019
Targeting FLT3 mutations in AML: review of current knowledge and evidenceNaval Daver, Richard F Schlenk, Nigel H Russell, et al.
British Journal of Haematology|November 20, 2021
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trialsRichard Dillon, Robert K Hills, Alan K Burnett, et al.
Blood|November 2, 2002
CMV infection following nonmyeloablative allogeneic stem cell transplantation using CampathRowena D Bainton, Jennifer L Byrne, Barbara J Davy, et al.
Pageof 12